Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: Using almotriptan as an example

Journal of Headache and Pain

Volumn 7, Issue 1, 2006, Pages 27-33

  Pascual, Julio ^a   Diener, Hans Christoph ^b   Massiou, Hélène ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Migraine; Postmarketing surveillance; Randomised controlled trials; Triptans

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ABDOMINAL PAIN; ANALGESIA; ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG EXPOSURE; DRUG PREFERENCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FRANCE; GERMANY; HUMAN; INFORMATION PROCESSING; META ANALYSIS; MIGRAINE; NAUSEA; PATIENT SATISFACTION; POSTMARKETING SURVEILLANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SOMNOLENCE; SPAIN; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

HUMANS; INTERNATIONAL COOPERATION; MIGRAINE DISORDERS; PAIN MEASUREMENT; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 33644784007     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-006-0266-6     Document Type: Article

References (32)

1. Silberstein SD (2000) Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754-762
2. Robbins L (2002) Triptans versus analgesics. Headache 42:903-907
3. Diener HC, Kaube H, Limmroth V (1999) Antimigraine drugs. J Neurol 246:515-519
4. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346:257-270
5. Silberstein SD (2004) Migraine. Lancet 363:381-391
6. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358:1668-1675
7. Pascual J (2005) Efficacy and tolerability of almotriptan in postmarketing surveillance studies. Eur Neurol 53[Suppl 1]:34-40
8. American Academy of Family Physicians (2004) Levels of evidence in AFP. Available at: http://www.aafp.org/x17444.xml. Accessed September 26, 2004
9. Edmeads J (2005) Defining response in migraine: Which endpoints are important? Eur Neurol 53[Suppl 1]:22-28
10. Cady RK, Sheftell F, Lipton RB et al (2000) Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin Ther 22:1035-1048
11. Pascual J, Cabarrocas X (2002) Within-patient early versus delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache 42:28-31
12. Pascual J (2002) Clinical benefits of early triptan therapy for migraine. Headache 42[Suppl 1]:S10-S17
13. Mathew NT (2003) Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 43:1075-1079
14. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X (2004) Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 44:318-322
15. Lipton RB, Hamelsky SW, Dayno JM (2002) What do patients with migraine want from acute migraine treatment? Headache 42[Suppl 1]:S3-S9
16. Davies GM, Santanello N, Lipton R (2000) Determinants of patient satisfaction with migraine therapy. Cephalalgia 20:554-560
17. Lipton RB, Bigal ME, Goadsby PJ (2004) Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia 24:321-332
18. Breslau N, Rasmussen BK (2001) The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology 56[Suppl 1]:S4-S12
19. Lipton RB, Stewart WF (1998) Migraine headaches: Epidemiology and comorbidity. Clin Neurosci 5:2-9
20. Breslau N, Merikangas K, Bowden CL (1994) Comorbidity of migraine and major affective disorders. Neurology 44[Suppl 7]:S17-S22
21. Joish VN, Cady PS, Bennett DM, Harris RB (2000) An epidemiological case-control study of migraine and its associated comorbid conditions. Ann Epidemiol 10:460
22. Shechter AL, Lipton RB, Silberstein SD (2001) Migraine comorbidity. In: Silberstein SD, Lipton RD, Dalessio DJ (eds) Wolff's headache and other headache pain. Oxford University Press, New York, pp 108-118
23. Ruoff GE (2004) Migraine comorbidity: Consequent pharmacologic strategies for treatment. Headache Pain 15:9-15
24. Atuah KN, Hughes D, Pirmohamed M (2004) Clinical pharmacology: Special safety considerations in drug development and pharmacovigilance. Drug Saf 27:535-554
25. Lipton RB (2001) Studying the migraine studies: Methodological issues in comparative trials of acute medications. Am J Clin Proc 1:51-57
26. Pascual J, Lainez JM, Leira R et al (2003) Almotriptan in the treatment of migraine attacks in clinical practice: Results of the TEA 2000 observational study. Neurologia 18:7-17
27. Pascual J, Tranche S, Leira R et al (2003) Almotriptan in clinical practice: Experience in primary care vs neurology setting. Headache 43:525
28. Diener HC (2005) Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache 45:624-631
29. Massiou H, Pradalier A, Donnet A, Lanteri-Minet M, Allaf B (2005) Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks: MIgraine - Satisfaction with Treatment: Reality with ALmogran (MISTRAL) study. Eur Neurol (in press)
30. Geraud G, Lanteri-Minet M, Lucas C, Valade D (2004) French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 26:1305-1318
31. Gallagher RM, Kunkel R (2003) Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache 43:36-44
32. Dodick DW (2001) Oral almotriptan in the treatment of migraine: Safety and tolerability. Headache 41:449-455